# of Displayed Technologies: 2 / 2


Novel gapmers targeting HOXB-AS3 for Acute Myeloid Leukemia Treatment
TS-037979 — A novel treatment for acute meloid leukemia.
The expression of long non-coding RNAs (lncRNAs) in older adults with cytogenetically normal acute myeloid leukemia (CN-AML) is reported to have prognostic significance. lncRNA HOXB-AS3 was identified among the top up-regulated lncRNAs in NPM1-mutated CN-AML cases. Aberrant expression of HOX genes…
  • College: College of Medicine (COM)
  • Inventors: Garzon, Ramiro; Dorrance, Adrienne; Kauppinen, M.Sc., Ph.D., Sakari; Lee, Robert; Papaioannou, Dimitrios
  • Licensing Officer: He, Panqing

Targeting EGFL7 in AML
TS-037353 — Treatment of blood cancer with anti-EGFL7 antibody.
Despite recent progress in understanding acute myeloid leukemia (AML) biology and the use of intensive treatments, the long-term overall survival is only 30-40% in younger (<60 years) and <10% in older adult AML patients. This highlights the urgent need for novel therapeutic approaches for a…
  • College: College of Medicine (COM)
  • Inventors: Dorrance, Adrienne; Garzon, Ramiro; Shen, Changxian
  • Licensing Officer: Davis, Stewart

Loading icon